MedTrace Logo

Study Conducted to Further Understand the Elimination Pathways, Metabolite Profile and PK Profile of 14C-estetrol

NCT02720224 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 6

Last updated 2019-02-15

Study results available
· View outcomes & findings →

Summary

This study is being conducted to further understand the elimination pathways, metabolite profile and pharmacokinetic (PK) profile of carbon 14 labelled estetrol (\[14C\] estetrol).

Conditions

Interventions

DRUG

Estetrol

15 mg \[14C\]-estetrol containing approximately 2.8 MBq (76 μCi) 14C

Sponsors & Collaborators

  • Quotient Clinical

    collaborator OTHER

  • Estetra

    lead INDUSTRY

Principal Investigators

  • Litza McKenzie, MBChB · Quotient Clinical

Study Design

Allocation
NA
Purpose
OTHER
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
30 Years
Max Age
65 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-02-29
Primary Completion
2016-03-31
Completion
2016-04-30

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02720224 on ClinicalTrials.gov